Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin +/- Bevacizumab in Advanced HER2- Breast Cancer
NCT06539559Phase 2Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06539559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539559.